Works matching DE "INDUCTION chemotherapy"

Results: 684
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    What does a non-response to induction chemotherapy imply in high-risk medulloblastomas?

    Published in:
    Journal of Neuro-Oncology, 2021, v. 153, n. 3, p. 425, doi. 10.1007/s11060-021-03777-9
    By:
    • Adelon, Jihane;
    • Dufour, Christelle;
    • Foulon, Stéphanie;
    • Masliah Planchon, Julien;
    • Meyronnet, David;
    • Bourdeaut, Franck;
    • Palenzuela, Gilles;
    • Fouyssac, Fanny;
    • Raimbault, Sandra;
    • De Carli, Emilie;
    • Klein, Sébastien;
    • Pagnier, Anne;
    • Bertozzi, Anne-Isabelle;
    • Rome, Angélique;
    • David, Audrey;
    • Chabaud, Sylvie;
    • Faure-Conter, Cécile
    Publication type:
    Article
    12

    Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands.

    Published in:
    World Journal of Urology, 2022, v. 40, n. 6, p. 1469, doi. 10.1007/s00345-022-03987-4
    By:
    • Reesink, Daan J.;
    • van de Garde, Ewoudt M. W.;
    • van der Nat, Paul;
    • Somford, Diederik M.;
    • Los, Maartje;
    • Horenblas, Simon;
    • van Melick, Harm H. E.;
    • for the Santeon MIBC Study Group;
    • Biesma, D. H.;
    • Stijns, P. E. F.;
    • Lavalaye, J;
    • De Bruin, P. C.;
    • Peters, B. J. M.;
    • Berends, M;
    • Richardson, R;
    • Van Andel, J;
    • Klaver, O. S.;
    • Haberkorn, B. C. M.;
    • Van Rooijen, J. M.;
    • Korthorst, R. A.
    Publication type:
    Article
    13
    14

    The prognostic impact of the lymphocyte-to-C-reactive protein ratio in patients with unresectable or recurrent advanced gastric cancer treated with first- and second-line treatment.

    Published in:
    Surgery Today, 2023, v. 53, n. 8, p. 940, doi. 10.1007/s00595-022-02638-w
    By:
    • Matsunaga, Tomoyuki;
    • Saito, Hiroaki;
    • Fukumoto, Yoji;
    • Kuroda, Hirohiko;
    • Taniguchi, Kenjiro;
    • Takahashi, Sadamu;
    • Osaki, Tomohiro;
    • Iwamoto, Akemi;
    • Fukuda, Kenji;
    • Shimizu, Shota;
    • Shishido, Yuji;
    • Miyatani, Kozo;
    • Fujiwara, Yoshiyuki
    Publication type:
    Article
    15
    16
    17

    A prospective phase II randomized study of docetaxel combined with lobaplatin versus TPF regimen induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 20, p. 18081, doi. 10.1007/s00432-023-05497-1
    By:
    • Zhang, Mang;
    • Chen, Yu;
    • Wu, Weili;
    • Jin, Feng;
    • Li, Yuanyuan;
    • Long, Jinhua;
    • Luo, Xiuling;
    • Gong, Xiuyun;
    • Chen, Xiaoxiao;
    • Liu, Lina;
    • Tang, Hong;
    • Wang, Ziqi
    Publication type:
    Article
    18
    19
    20
    21

    Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 9, p. 2437, doi. 10.1007/s00432-021-03782-5
    By:
    • Morimoto, Kenji;
    • Uchino, Junji;
    • Yokoi, Takashi;
    • Kijima, Takashi;
    • Goto, Yasuhiro;
    • Nakao, Akira;
    • Hibino, Makoto;
    • Takeda, Takayuki;
    • Yamaguchi, Hiroyuki;
    • Takumi, Chieko;
    • Takeshita, Masafumi;
    • Chihara, Yusuke;
    • Yamada, Takahiro;
    • Hiranuma, Osamu;
    • Morimoto, Yoshie;
    • Iwasaku, Masahiro;
    • Kaneko, Yoshiko;
    • Yamada, Tadaaki;
    • Takayama, Koichi
    Publication type:
    Article
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach.

    Published in:
    Internal Medicine Journal, 2025, v. 55, n. 5, p. 749, doi. 10.1111/imj.70010
    By:
    • Tedjaseputra, Aditya;
    • Tey, Amanda;
    • Nalpantidis, Anastasios;
    • Grigoriadis, George;
    • Fleming, Shaun;
    • Vilcassim, Shahla;
    • Fedele, Pasquale L.;
    • Low, Michael Sze Yuan;
    • Yeh, Paul;
    • Gilbertson, Michael;
    • Bennett, Ashwini;
    • Gregory, Gareth P.;
    • Oh, Danielle;
    • Gairns, Donna;
    • Kaplan, Zane;
    • Chunilal, Sanjeev D.;
    • Brown, Susan;
    • Opat, Stephen;
    • Chua, Chong C.;
    • Shortt, Jake
    Publication type:
    Article
    33
    34
    35
    36

    Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial.

    Published in:
    Cancer Biology & Medicine, 2022, v. 19, n. 7, p. 1089, doi. 10.20892/j.issn.2095-3941.2021.0026
    By:
    • Jingjing Wu;
    • Fenghua Gao;
    • Wenhua Wang;
    • Xudong Zhang;
    • Meng Dong;
    • Lei Zhang;
    • Xin Li;
    • Ling Li;
    • Zhenchang Sun;
    • Xinhua Wang;
    • Xiaorui Fu;
    • Linan Zhu;
    • Mengjie Ding;
    • Songtao Niu;
    • Zhaoming Li;
    • Yu Chang;
    • Feifei Nan;
    • Jiaqian Yan;
    • Hui Yu;
    • Xiaolong Wu
    Publication type:
    Article
    37
    38
    39
    40
    41
    42

    Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.

    Published in:
    Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.999822
    By:
    • Tettero, Jesse M.;
    • Al-Badri, Waleed K. W.;
    • Ngai, Lok Lam;
    • Bachas, Costa;
    • Breems, Dimitri A.;
    • van Elssen, Catharina H. M. J.;
    • Fischer, Thomas;
    • Gjertsen, Bjorn T.;
    • van Gorkom, Gwendolyn N. Y.;
    • Gradowska, Patrycja;
    • Greuter, Marjolein J. E.;
    • Griskevicius, Laimonas;
    • Juliusson, Gunnar;
    • Maertens, Johan;
    • Manz, Markus G.;
    • Pabst, Thomas;
    • Passweg, Jakob;
    • Porkka, Kimmo;
    • Löwenberg, Bob;
    • Ossenkoppele, Gert J.
    Publication type:
    Article
    43
    44
    45
    46
    47
    48
    49

    Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy.

    Published in:
    Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.953020
    By:
    • Marín-Jiménez, Juan A.;
    • Oliva, Marc;
    • Martín, Paloma Peinado;
    • Cabezas-Camarero, Santiago;
    • Serrahima, Maria Plana;
    • Vázquez Masedo, Gonzalo;
    • Lozano Borbalas, Alicia;
    • Cabrera Martı'n, María N.;
    • Esteve, Anna;
    • Iglesias Moreno, María C.;
    • Vilajosana Altamis, Esther;
    • Arribas Hortigüela, Lorena;
    • Taberna Sanz, Miren;
    • Pérez-Segura, Pedro;
    • Mesía, Ricard
    Publication type:
    Article
    50